Thoracic bilateral sympathectomy attenuates oxidative stress and prevents ventricular remodelling in experimental pulmonary hypertension
Carregando...
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS INC
Autores
WIGGENHAUSER, Lucas Moritz
SIMAS, Rafael
MEDEIROS, Geisla
SILVA, Fernanda Beatriz da
OGATA, Daniel Cury
KRENNING, Guido
Citação
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, v.61, n.6, p.1337-1345, 2022
Resumo
OBJECTIVES: Pulmonary arterial hypertension (PAH) is a cardiopulmonary disease that affects the pulmonary vasculature, leading to increased afterload and eventually right ventricular (RV) remodelling and failure. Bilateral sympathectomy (BS) has shown promising results in dampening cardiac remodelling and dysfunction in several heart failure models. In the present study, we investigated whether BS reduces pulmonary arterial remodelling and mitigates RV remodelling and failure. METHODS: PAH was induced in male Wistar rats by intraperitoneal injection of monocrotaline. Rats were divided into 3 groups, involving untreated PAH (n = 15), BS-treated PAH (n = 13) and non-manipulated control rats (n = 13). Three weeks after PAH induction, the rats were anaesthetized and RV function was assessed via the pressure-volume loop catheter approach. Upon completion of the experiment, the lungs and heart were harvested for further analyses. RESULTS: BS was found to prevent pulmonary artery remodelling, with a clear reduction in alpha-smooth muscle actin and endothelin-1 expression. RV end-systolic pressure was reduced in the BS group, and preload recruitable stroke work was preserved. BS, therefore, mitigated RV remodelling and cardiomyocyte hypertrophy and diminished oxidative stress. CONCLUSIONS: We showed that thoracic BS may be an important treatment option for PAH patients. Blockade of the sympathetic pathway can prevent pulmonary remodelling and protect the RV from oxidative stress, myocardial remodelling and function decay. Pulmonary arterial hypertension (PAH) is a cardiopulmonary disease that affects both the pulmonary vasculature and the right ventricle (RV).
Palavras-chave
Sympathetic blockade, Pulmonary hypertension, Ventricular remodelling, Pulmonary artery remodelling, Oxidative stress
Referências
- Calderaro D, 2019, ARQ BRAS CARDIOL, V113, P419, DOI 10.5935/abc.20190188
- Channick RN, 2001, LANCET, V358, P1119, DOI 10.1016/S0140-6736(01)06250-X
- Chen SL, 2015, CIRC-CARDIOVASC INTE, V8, DOI 10.1161/CIRCINTERVENTIONS.115.002837
- Chen SL, 2013, J AM COLL CARDIOL, V62, P1092, DOI 10.1016/j.jacc.2013.05.075
- Cho YJ, 2009, COMPARATIVE MED, V59, P350
- Silva RDCE, 2020, J THORAC CARDIOV SUR, V160, pE135, DOI 10.1016/j.jtcvs.2019.09.031
- Damon DH, 2005, AM J PHYSIOL-HEART C, V288, pH2785, DOI 10.1152/ajpheart.00354.2004
- Farkas L, 2009, J CLIN INVEST, V119, P1298, DOI 10.1172/JCI36136
- Good RB, 2015, AM J PATHOL, V185, P1850, DOI 10.1016/j.ajpath.2015.03.019
- Gorski PA, 2015, CELL METAB, V21, P183, DOI 10.1016/j.cmet.2015.01.005
- Klinger James R, 2017, Am J Cardiol, V120, pS71, DOI 10.1016/j.amjcard.2017.06.012
- Liu RX, 2017, INT J BIOCHEM CELL B, V88, P100, DOI 10.1016/j.biocel.2017.05.001
- Mercurio V, 2019, PULM CIRC, V9, DOI 10.1177/2045894019868620
- Na S, 2014, HYPERTENSION, V63, P309, DOI 10.1161/HYPERTENSIONAHA.113.01979
- Prins KW, 2016, CARDIOL CLIN, V34, P363, DOI 10.1016/j.ccl.2016.04.001
- Sheng Yulan, 2018, Int J Physiol Pathophysiol Pharmacol, V10, P17
- Thenappan T, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.j5492
- TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858
- Tuder RM, 2013, J AM COLL CARDIOL, V62, pD4, DOI 10.1016/j.jacc.2013.10.025
- Zanoni FL, 2017, J THORAC CARDIOV SUR, V153, P855, DOI 10.1016/j.jtcvs.2016.11.037
- Zhao YP, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1090-2
- Zhou L, 2015, JACC-CARDIOVASC INTE, V8, P2013, DOI 10.1016/j.jcin.2015.09.015
- Zimmer A, 2020, MOL CELL BIOCHEM, V464, P93, DOI 10.1007/s11010-019-03652-2